Pathways to treating chronic inflammatory diseases

An EU-funded project has developed new approaches to tackling chronic inflammatory diseases. These will be used to create precise and individualised treatment options, potentially leading to faster diagnosis, more effective treatments and even cures.

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Bosnia and Herzegovina
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czechia
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Bosnia and Herzegovina
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czechia
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Georgia


  Infocentre

Published: 28 February 2019  
Related theme(s) and subtheme(s)
Health & life sciencesGenomics  |  Major diseases  |  Medical research
Research policyHorizon 2020
Countries involved in the project described in the article
Belgium  |  Croatia  |  Denmark  |  Germany  |  Greece  |  Italy  |  Luxembourg  |  Switzerland  |  United Kingdom
Add to PDF "basket"

Pathways to treating chronic inflammatory diseases

Image

z

Chronic inflammatory disease is causing an increasing medical and societal burden. Conditions such as inflammatory bowel disease, rheumatoid arthritis and autoimmune conditions are estimated to affect 1 in 10 people in Europe. However, at present, the treatment options available are limited and ineffective, and there are no identified pathways to finding a cure.

The EU-funded SYSCID project has developed an approach to create precise and individualised treatment options for patients with chronic inflammatory diseases. The aim is to enable biomarkers, or disease signatures, to be identified that indicate the presence of disease so that conditions can be diagnosed and treated quickly and effectively.

Initially, this will provide precision medicine and personalised treatment options which can be adjusted to an individual patient’s specific condition. The approach will also help to determine the cause of conditions and the development of cures. The project, which ends in March 2022, is continuing to develop the approach.

‘The project has revealed information about treatment options for patients with inflammatory bowel disease, rheumatoid arthritis and systemic lupus erythematodes,’ says project coordinator Philip Rosenstiel of Christian-Albrechts-Universität zu Kiel in Germany. ‘Initial studies into how disease affects the body’s cellular programming has improved our understanding of how some treatment options work.’

Understanding the molecular level

Inflammatory diseases manifest at different molecular layers within the body. SYSCID looks at disease at three of these: the epigenetic or gene expression level, the cell programming or transcriptional level, and the gut bacteria or microbiome level.

The project set out to find core disease signatures in large datasets collected over time. Initial studies monitored over 300 patients undergoing first-time treatment for chronic inflammatory diseases.

This has provided data on cellular programming that can be used to understand how cells influence gene expression. This information has already revealed that treatment with an antibody called vedolizumab modulates patients’ innate disease immunity.

Reprogramming disease

The SYSCID project is following three distinct pathways to innovation. Specifically, it focuses on big-data analysis. Complex statistics and bioinformatics enable clinical details to be derived from the huge datasets collected from patients. This simplified information can be easily interpreted and understood by both clinicians and patients.

Project researchers are also focusing on understanding disease at the single-cell level. This approach aims to enable the identification of biomarkers, easier diagnosis of chronic inflammatory diseases, and a predictive model of disease outcomes.

The project is also hoping to understand the epigenetics – changes in genetic behaviour – that govern the onset of inflammatory diseases. This could enable diseases to be cured by erasing, editing or reprogramming parts of a patient’s genome.

‘SYCID will create a prediction framework for disease outcome and guide therapy decisions on an individual patient level,’ says Rosenstiel. ‘This will mean that the right therapy is chosen at the right time. The consortium is also targeting new therapy approaches to ‘reprogramme’ disease through epigenome editing. In this way, diseases will not only be managed but cured.’

The project brings together experts from major scientific disciplines, such as genomics, with clinicians, gastroenterologists and rheumatologists from across Europe. These key players have set up collaborations to enable rapid progress.

Project details

  • Project acronym: SYSCID
  • Participants: Germany (Coordinator), Switzerland, United Kingdom, Belgium, Luxembourg, Denmark, Italy, Greece, Croatia
  • Project N°: 733100
  • Total costs: € 16 018 111
  • EU contribution: € 14 456 236
  • Duration: Jan 2017 to March 2022

See also

 

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also
Project website
Project details